Search

Showing total 5,167 results

Search Constraints

Start Over You searched for: Search Limiters Full Text Remove constraint Search Limiters: Full Text Journal british journal of pharmacology Remove constraint Journal: british journal of pharmacology Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
5,167 results

Search Results

1. BJP is changing its requirements for scientific papers to increase transparency.

2. Considering and reporting sex as an experimental variable II: An update on progress in the British Journal of Pharmacology.

3. Cigarette Smoke Up-regulates PDE3 and PDE4 to Decrease cAMP in Airway Cells

5. Recent changes in the British Journal of Pharmacology: widening scope and improving author and editor experience.

6. Editorial policy regarding the citation of preprints in the British Journal of Pharmacology (BJP).

7. Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells

8. Instructions to Authors.

10. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

11. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin

12. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes

13. AMP-activated protein kinase (AMPK)-dependent and -independent pathways regulate hypoxic inhibition of transepithelial Na+ transport across human airway epithelial cells

14. A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

15. The carbon monoxide releasing molecule (CORM-3) inhibits expression of vascular cell adhesion molecule-1 and E-selectin independently of haem oxygenase-1 expression

16. Fifty years with aspirin and platelets.

17. Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?

18. Arylamine N-acetyltransferases: a structural perspective. Comments regarding the BJP paper by Zhou et al., 2013.

19. Bad statistical practice in pharmacology (and other basic biomedical disciplines): you probably don't know P.

20. GPCR theme editorial.

21. Instructions to Authors.

22. A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research.

23. N-acetylcysteine as a new prominent approach for treating psychiatric disorders.

24. Nicotinic acetylcholine receptors.

25. Pharmacology of bisphosphonates in pain.

26. Opioid research in the time of the opioid crisis.

27. Current pharmacological treatments for COVID-19: What's next?

28. PDE4 in the human heart - major player or little helper?

29. Oiling the wheels of discovery.

30. Endothelium in pharmacology: 30 years on.

31. Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?

33. Retraction. Fenofibrate improves the impaired endothelial progenitor cell function through inhibiting eNOS uncoupling in diabetic mice.

34. Planning experiments: Updated guidance on experimental design and analysis and their reporting III.

35. Salt, inflammation, IL-17 and hypertension.

36. Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance.

37. Transparency in Research involving Animals: The Basel Declaration and new principles for reporting research in BJP manuscripts.

38. GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery.

39. Neonicotinoid insecticides differently modulate acetycholine-induced currents on mammalian α7 nicotinic acetylcholine receptors.

40. Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.

41. Forging a modern generation of polyphenol-based therapeutics.

42. Supra-physiological efficacy at GPCRs: superstition or super agonists?

44. The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by ß-amyloid peptide.

45. Shikonin reduces oedema induced by phorbol ester by interfering with IkappaBalpha degradation thus inhibiting translocation of NF-kappaB to the nucleus.

46. Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase.

48. Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. II. Effects after intrathecal administration.

49. Purinergic signalling.

50. The discovery of nitric oxide and its role in vascular biology.